stockrow
Saturday 7 November 2026
Export BIORQ’s income statement to Excel — free account
Biora Therapeutics, Inc.
BIORQ Healthcare Biotechnology
Biora Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $4,000.00, down 98.7% from fiscal 2022.
0.00
0.00
NaN
Follow BIORQ
Alert me
| Sep '24 | Jun '24 | Mar '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 3 | 3 | — |
+8 more TTM periods Free account |
| 27.98% | 82.39% | 108.06% | 121.86% | ||
| (128.19%) | (254.92%) | (290.85%) | (292.93%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
27.81% | 243.75% | 308.84% | 290.36% | |
Average Days of Receivables |
354.38 | 347.26 | 535.77 | 0.00 | |
Free Cash Flow per Share |
(1.26) | (13.57) | (16.72) | (19.47) | |
Free Cash Flow |
(46.18) | (48.47) | (48.98) | (48.59) | |
Capital Expenditures |
(0.26) | (0.24) | (0.08) | (0.09) | |
| Other line items | |||||
Cash ROIC |
55.17% | 126.48% | 111.03% | 119.98% | |
Accounts Receivable Turnover |
1.06 | 1.05 | 0.68 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,957.16% | 3,631.25% | 5,295.18% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
3,951.68% | 4,334.84% | 6,786.79% | 0.00% | |
Share Based Compensation of Revenue |
664.32% | 1,757.99% | 2,791.07% | 0.00% | |
Interest Coverage |
(8.31) | (8.60) | (6.78) | (6.84) | |
Operating CF/Net income |
1.46 | 0.56 | 0.44 | 0.39 | |
Depreciation/Fixed assets |
3.52 | 2.82 | 3.24 | 1.87 | |
Capex/Depreciation |
(0.06) | (0.07) | (0.02) | (0.04) | |
Revenue per Share |
0.02 | 0.24 | 0.19 | 0.00 | |
Operating CF per Share |
(1.26) | (13.50) | (16.69) | (19.43) | |
Capex per Share |
(0.01) | (0.07) | (0.03) | (0.04) | |
Capex to Sales |
0.29 | 0.28 | 0.14 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026